Through a detailed exploration of Irisin and Treg interactions, we anticipate identifying potential therapeutic targets that could lead to innovative treatments for Alzheimer’s disease [9], Parkinson’s disease [10], and other related conditions. Here, FNDC5 is linked to early-onset autosomal dominant Alzheimer disease.